Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer.
Ratings
0 / 5
0 ratings in the last 12 months
5
4
3
2
1
CEO
Dr. Hans T. Schambye, M.D.,PhD$18.7M
Market Cap • 23/04/20242019
(há 5 anos)
2020
(4 years ago)
NASDAQ
Listagem
Copenhagen
45
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
GLTOSó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.